Followers | 504 |
Posts | 10140 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
Sunday, April 12, 2015 11:17:20 AM
bullish
bounce off moving average
## source: finance.yahoo.com
Fri, 10 Apr 2015 22:06:00 GMT ~ Nasdaq stocks posting largest percentage increases
[AP] - A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: Tonix Pharma rose 26.5 percent to $7.40. Trillium Therapeutic rose 16.4 percent to $11.12. Ebix Inc. rose 14.3 percent to ...
read full: http://sg.finance.yahoo.com/news/nasdaq-stocks-posting-largest-percentage-220237991--finance.html
*********************************************************
Sat, 04 Apr 2015 17:04:08 GMT ~ GALMED PHARMACEUTICALS LTD. Financials
read full: http://finance.yahoo.com/q/is?s=glmd&annual
*********************************************************
Wed, 01 Apr 2015 15:20:01 GMT ~ Biotechs Raising New Capital in Droves
read full: http://247wallst.com/healthcare-business/2015/04/01/biotechs-raising-new-capital-in-droves/
*********************************************************
Wed, 01 Apr 2015 12:00:00 GMT ~ Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations
[PR Newswire] - TEL AVIV, Israel, April 1, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced that it has appointed George Tonelli as Vice President of Clinical Operations. Mr. Tonelli brings 20+ years of progressive experience in clinical operations, development and regulatory affairs. From 2005 to 2014, Mr. Tonelli planned and executed multiple clinical trials in the therapeutic area of Diabetes Mellitus at MannKind Corporation, culminating in the FDA approval of Afrezza®. Prior to MannKind, Mr. Tonelli held several leadership positions in clinical development and project management at Innapharma. Mr. Tonelli began his career in regulatory affairs in the Medical Research Division of American Cyanamid (Lederle Labs).
read full: http://finance.yahoo.com/news/galmed-pharmaceuticals-announces-appointment-george-120000463.html
*********************************************************
Tue, 31 Mar 2015 12:00:00 GMT ~ Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update
[PR Newswire] - TEL AVIV, Israel, March 31, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization ...
read full: http://finance.yahoo.com/news/galmed-pharmaceuticals-reports-full-2014-120000693.html
*********************************************************
$GLMD charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$GLMD company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/GLMD/company-info
Ticker: $GLMD
OTC Market Place: Not Available
CIK code: not found
Company name: Galmed Pharmaceuticals Ltd.
Incorporated In: USA
$GLMD share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: l PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"> OTC Markets | Official site of the OTCQX, OTCQB and OTC Pink Marketplaces featuring Free Stock & Bond Quotes, Trade Prices, Chart, Financials and Company News & Information for Investors, Companies and Traders - OTCMarkets.com var appSection = "" ; var tierGroupId = undefined; var symbol = "GLMD"; var jq191 = $.noConflict(true); var appNav = new OTCMarketsAppNav(); var iqCaller = new OtcIQCalls(); var commonCaller = new PinkCommonCalls(); var contentCaller = new PinkContentCalls(); var edgarCaller = new PinkEdgarCalls(); var decorateSymbols = new SymbolDecorator(commonCaller); height="0" width="0" style="display:none;visibility:hidden"> (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer',"GTM-N65JXN"); OTC Markets Home Marketplaces Market Activity Current Market Closing Summary Broker Dealer Data Corporate Actions Short Sale Data Reg SHO Data News Company News & Financials Press Releases Videos & Presentations RSS Feeds OTC Markets Events OTC Markets Newsletter OTC Markets Press Center Services Companies Investors Market Data Trading Research Stock Screener OTCQX Company List Company Directory Service Provider Directory OTCQX Advisor List Broker Dealer Directory Prohibited Attorney List Symbology Glossary Learn Our Marketplaces Market 101 Investor Protection Reporting Requirements American Depositary Receipts (ADRs) Apply for OTCQX - Our Best Marketplace Comply with New OTCQB Requirements Information for OTC Pink Companies How to Get Traded Caveat Emptor Policy FINRA & SEC Rules Whitepapers FAQs tierTitle = getTierTitle(undefined); Company Directory | Stock Screener OTC Market Totals - Securities - Dollar Volume - Share Volume - Trades var glossaryDecorator = new GlossaryDecorator (contentCaller) ; $('p').each (function () { var glossaryId = $(this).attr('glossaryId'); if (glossaryId) this.psGlossaryId=glossaryId; }); if (document.getElementById('p')) glossaryDecorator .doSection (document.getElementById ('p')); $('#quoteEntry input#quoteBox').focus(function() { toggleFieldValue(this, 'Enter Symbol/Company Name', ''); }).blur(function() { toggleFieldValue(this, '', 'Enter Symbol/Company Name'); }); var security = new SecurityInfo(233186, 681810, "Galmed Pharmaceuticals Ltd.", "GALMED PHARMA", "GLMD", "Nasdaq", false, false, undefined, "Common Stock", undefined, undefined, false, false, true, false, undefined, undefined, undefined, false, 1.0, undefined); var symbolSecurity = (security.symbol)? security.symbol:security.secId; var initNewsId = undefined; var glossaryDecorator = new GlossaryDecorator (contentCaller) ; Quote Charts Company Profile News Financials Filings and Disclosure Short Sales Insider Disclosure Research Reports Videos and Presentations GLMD Galmed Pharmaceuticals Ltd. Common Stock Nasdaq function doOTCQX30Logo(url) { var CONSTITUENTS_DATA; if ($.browser.msie) { var http = new XDomainRequest(); http.open("get", url); http.onload = function() { var data = http.responseText; if (typeof data === "undefined") return; CONSTITUENTS_DATA = JSON.parse(data); displayIndexLogo(CONSTITUENTS_DATA); }; http.send(null); } else { $.ajax({ type : "GET", url : url, data : {}, success : function(data) { if (typeof data === "undefined") return; CONSTITUENTS_DATA = JSON.parse(data); displayIndexLogo(CONSTITUENTS_DATA); } }); } } function displayIndexLogo(constituents) { if (typeof constituents === undefined) { if (console && console.log) { console.log("Unable to load constituents."); } } var result = $.grep(constituents, function(e){ return e.ticker == security.symbol; }); if (result.length > 0) { $('.tierLogoContainer a').attr('href', '/index/.OTCQX30/quote'); $('.tierLogo').attr('src', '/content/doc/otcm/tier/logo/small/otcqx30.png'); $('.tierLogo').attr('alt','OTCM QX ADR 30 Index Constituent'); $('.tierLogo')[0].psGlossaryId='otcqx30-constituent'; handler.decorateGlossary(); } } var json_url = "http://s3.amazonaws.com/content.otcmarkets.com/constituents/otcqx_30_list.json"; doOTCQX30Logo(json_url); var handler = new QuoteHandler(); handler.checkCaveat(); var tradeHeaderHandler; if (!window.location.href.match('quote')) tradeHeaderHandler = new TradeHeaderHandler(iqCaller, window.document.getElementById('quoteBar')); if (security.symbol == null || security.symbol.length == 0) { $('#quoteUnderArrowTabs li.eqOnly').hide(); } $('img').each(function () { var glossaryId = $(this).attr('glossaryId'); if (glossaryId) this.psGlossaryId = glossaryId; }); handler.decorateGlossary(); $("#title").html('Company Info'); var shortDesc = undefined; var longDesc = undefined; function toggleFullDescription(full) { if (full) { $("#businessContent p").html(longDesc); }else { $("#businessContent p").html(shortDesc); } } Contact Info Business Description Not Available Update Company Profile Financial Reporting/Disclosure Reporting Status Alternative Reporting Standard
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$GLMD extra dd links
Company name: Galmed Pharmaceuticals Ltd.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=GLMD+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=GLMD+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=GLMD+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/GLMD/news - http://finance.yahoo.com/q/h?s=GLMD+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/GLMD/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/GLMD/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=GLMD+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/GLMD
DTCC (dtcc.com): http://search2.dtcc.com/?q=Galmed+Pharmaceuticals+Ltd.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Galmed+Pharmaceuticals+Ltd.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Galmed+Pharmaceuticals+Ltd.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/GLMD
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/GLMD/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/GLMD/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=GLMD&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=GLMD
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/GLMD/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=GLMD+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=GLMD+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=GLMD
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=GLMD
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=GLMD+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/GLMD/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=GLMD+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/GLMD.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=GLMD
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/GLMD/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/GLMD/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/GLMD
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/GLMD
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/GLMD:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=GLMD
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=GLMD
$GLMD DD Notes ~ http://www.ddnotesmaker.com/GLMD
Recent GLMD News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/20/2024 08:46:04 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 09/20/2024 06:18:08 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 09/20/2024 06:17:11 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/19/2024 11:13:44 AM
- Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases • PR Newswire (US) • 09/19/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/16/2024 08:15:24 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/10/2024 04:15:08 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/09/2024 08:30:22 PM
- Form F-1 - Registration statement for certain foreign private issuers • Edgar (US Regulatory) • 08/30/2024 08:25:56 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/30/2024 08:15:20 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/28/2024 08:30:23 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/27/2024 08:15:33 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/11/2024 12:50:53 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/05/2024 08:16:13 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/30/2024 08:30:08 PM
- Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 • PR Newswire (US) • 04/04/2024 09:06:00 PM
- Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis • PR Newswire (US) • 03/15/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:14:47 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 09:15:15 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 11/22/2023 09:48:47 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/20/2023 09:37:19 PM
- Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study • PR Newswire (US) • 11/20/2023 09:32:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 11/01/2023 08:15:07 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM